RC
OKUR

Rangeley Capital’s OnKure Therapeutics OKUR Stock Holding History

Rangeley Capital’s Portfolio OKUR Stock Details OKUR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$433K Hold
95,000
– – 0.4% 68
2026
Q1 		$393K Sell
95,000
-50,000
-34% -$154K 0.38% 56
2025
Q4 		$421K Sell
145,000
-10,490
-7% -$31.4K 0.35% 59
2025
Q3 		$428K Buy
155,490
+125,588
+420% +$311K 0.37% 58
2025
Q2 		$71.5K Buy
+29,902
New +$78.4K 0.09% 58

Other funds holding OKUR

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
SG
StepStone Group La Jolla, California $2.16B AUM 20.11% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Rangeley Capital's OKUR Position: Q2 2026 in Review

Rangeley Capital held its OnKure Therapeutics (OKUR) position steady in Q2 2026 at 95,000 shares worth $433K. The position accounts for 0.4% of the portfolio, ranked #68.

Rangeley Capital first reported a position in OKUR in Q2 2025 and has held it in 5 quarters since. 75 funds tracked by Wall St. Rank hold OKUR as of Q2 2026.

  • Rangeley Capital held 95,000 shares of OnKure Therapeutics worth $433K as of Q2 2026.
  • Rangeley Capital left its OnKure Therapeutics share count unchanged in Q2 2026.
  • OnKure Therapeutics made up 0.4% of Rangeley Capital's portfolio in Q2 2026, its #68 holding.
  • Rangeley Capital first reported a position in OnKure Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 75 funds tracked by Wall St. Rank held OnKure Therapeutics as of Q2 2026.

Based on Rangeley Capital's 13F filing for Q2 2026, filed 14 Aug 2026.